In particular, Wan et al. has demonstrated that the subset of type 2 innate lymphoid cells (ILC2s) is enriched in CRC and ILC2-derived IL-9 activate CD8 + to inhibit tumor growth, while anti-IL-9 reversed this effect in vivo[39]. The gene discussed is CD8A; the disease is neoplasm.